Viremia kinetics directly influence the clinical course and transmission dynamics of DENV, but many aspects of viral dynamics remain unknown. Non-human primates (NHP) have been used as a model system for DENV infection for decades. Here, we identify papers with experimentally-infected NHP and estimate the time to-and duration of viremia as well as estimate associations between these and serotype, inoculating dose, viremia assay, and species of NHP. We estimate the time to viremia in rhesus macaques to range from 2.63 to 3.32 days for DENV-2 and -1 and the duration to range from 3.13 to 5.13 days for DENV-4 and -2. We find no differences between non-human primates for time to viremia or duration, and a significant negative relationship between inoculating dose and duration of viremia. These results aid in understanding the transmission dynamics of sylvatic DENV non-human primates, an issue of growing importance as dengue vaccines become available. 
Introduction
Knowledge of the kinetics of dengue fever virus (DENV) within primate and non-primate hosts is a key to understanding transmission dynamics and identifying populations at risk for infection (Simmons et al., 2012) . Due to logistical and ethical obstacles, few studies have measured wildtype DENV viremia in humans over the course of an infection. Thus, non-human primates have been the major model system for comparison of viral dynamics between DENV serotypes and strains as well as evaluation of dengue therapeutics. While non-human primates differ from humans in pathological responses to DENV infection, estimates of duration of viremia that exist appear to be similar Koraka et al., 2007) , albeit with lower viral replication and limitation of virus to a subset of those tissues infected in humans (Zompi and Harris, 2012) .
In addition to serving as a potential model for human diseases, insight into the replication of DENV in non-human primates is important in its own right. Four serotypes of sylvatic DENV have been shown to circulate between non-human primates and arboreal Aedes mosquitoes in Southeast Asia (Rudnick et al., 1986) and sylvatic DENV serotype 2 is maintained in West Africa (Diallo et al., 2003) . These sylvatic viruses are ancestral to the four serotypes of DENV that are currently transmitted between humans by domestic and peridomestic Aedes (Vasilakis et al., 2011) . Populations living in areas surrounding sylvatic hotspots of DENV transmission are at risk of infection (Cardosa et al., 2009; Franco et al., 2011 ) from a transmission process that is poorly understood (Vasilakis and Weaver, 2008) . Importantly, it has recently been discovered that sylvatic DENV infection in humans can produce the most severe manifestation of dengue disease -dengue hemorrhagic fever (Cardosa et al., 2009; Franco et al., 2011) . In the light of recent advances in DENV vaccines (Guy et al., 2010; Durbin and Whitehead, 2010) , sylvatic reservoirs may play a key role in maintaining transmission over long time scales and may continue to expose human populations to new, genetically distinct viruses after human endemic transmission is controlled (Vasilakis et al., 2011) .
Isolations of sylvatic DENV have occurred at roughly 8 year intervals in Senegal over the past 50 years (Diallo et al., 2003) . The key determinants of cycle length are largely unknown. As the natural history of a pathogen has a direct influence on transmission dynamics (Keeling and Rohani, 2008) primates will be useful in ecological models of transmission (Althouse et al., 2012) and may generate hypotheses for the observed serotype-specific transmission patterns (Nisalak et al., 2003) and clinical manifestations (Balmaseda et al., 2006; Halsey et al., 2012) observed across DENV serotypes. It is the goal of the present study to examine the kinetics of DENV viremia in non-human primates through systematic review and individual pooled analysis. We conducted a literature review to identify experimental DENV infections of DENV-naïve monkeys. We find associations between time from inoculation to viremia and duration of viremia and several covariates of interest using mixed effects regression models. We report robust estimates of the time to detectable viremia and the duration of viremia using recently developed methods for handling doubly-interval censored data (Reich et al., 2009) .
Results

Literature
Literature searches returned 1092 unique papers (Fig. 1 ). Of these, 117 (11%) described dengue infection in non-human primates, 226 (21%) described observational/naturally occurring dengue infection in humans and not non-human primates, 91 (8%) were about another disease, 125 (11%) had no abstracts, and 533 (49%) described experimental studies involving humans and animal models (not involving NHP).
Fifty one published studies and three unpublished studies met the criteria for inclusion and were included in the analysis (Table 1) . Thirty six included rhesus macaque (Macaca mulatta), 7 cynomolgus macaques (Macaca fascicularis), 4 each with green monkeys (Chlorocebus aethiops sabaeus) and owl monkeys (Aotus nancymaae), 3 chimpanzee (Pan troglodytes), 2 each with spider monkey (Ateles geoffroyi) and pig-tailed macaques (Macaca nemestrina), and 1 each with common marmoset (Callithrix jacchus), patas (Erythrocebus patas), squirrel monkey (Saimiri sciureus), and White Handed Gibbon (Hylobates lar). The bulk of the studies were vaccine trials/challenge studies (34/51, 67%) the rest were experimental challenge trials (18/51 35%). 59 unique DENV genotypes were represented. 72 (10%) nonhuman primates were infected with DENV-4 4328S, 43 (6.1%) with DENV-2 S16803, and 40 (5.6%) with DENV-1 WP74 (see Supplementary Material) . Table 2 reports numbers of non-human primates by DENV serotype.
Associations with time to viremia and duration
Mixed effect models were fit with a random effect for study and were universally preferred over linear fixed effect models by AIC (see Supplementary Material). Intraclass correlation coefficients indicated strong heterogeneity by study (0.48, 95% CI: 0.37, 0.60) which could be due to differences among laboratories and assays employed. Mixed effect models assume non-human primates are exchangeable within studies, and account for heterogeneity between studies. Mixed effect models employed here do not take into account censoring, however only DENV-2 (p ¼0.001) and common marmoset samples (p ¼0.03) were associated with more censoring.
Tables 3 and 4 report the associations for serotype, log 10 inoculating dose, assay, and species of non-human primate with length of time to detectable viremia and duration of viremia in mixed effect models. Both univariate (with only the covariate of interest included) and multivariate (with all covariates included) models were fit. The multivariate models accounting for study heterogeneity indicated the time to detectable viremia for DENV-1 was statistically significantly longer than for DENV-4 and DENV-2 and -3 were not significantly different from DENV-4. Time to detectable viremia was statistically significantly longer in patas monkeys and marginally significantly shorter in spider monkeys than rhesus macaques; and time to detectable viremia was significantly shorter in those non-human primates assayed by immunofluorescence assays (IFA). Increasing log dose of inoculum was statistically significantly associated with shorter times to detectable viremias (Table 3) . Large study heterogeneity was present, with the variance of the random intercept equal to 1 day.
Duration of viremia was statistically significantly longer for DENV-1 and -2 as compared to DENV-4 after accounting for study heterogeneity. Duration for DENV-3 was not significantly different from DENV-4 (Table 4) . Adjusting for study, species, assay, and dose increased the difference in durations between DENV-1 and -2 and DENV-4. Changing the reference serotype to DENV-2 shows DENV-1, -3, and -4 to have statistically significantly shorter durations of viremia than DENV-2 (see Supplementary Material). Significantly longer durations of viremia were observed when assayed by RT-PCR and IFA compared to plaque-forming assays, adjusting for study, species, assay, and dose. No significant differences in viremia duration were observed across species, besides a significant shortening in patas monkeys (however, only 3 patas monkeys were tested) and a marginally significant shortening in green monkeys from rhesus monkeys. Duration of viremia was negatively associated with dose of inoculum, with durations decreasing by 0.44 days (95% CI: 0.18, 0.7) per log 10 increase in dose. Again, the variance of the random intercept was quite large (2.32 days).
Estimates of time to detectable viremia and duration of viremia
In rhesus macaques the median time to detectable viremia of DENV was 3.32 days (95% CI: 3.01, 3.65), 2.63 days (95% CI: 2.40, 2.89), 3.02 days (95% CI: 2.71, 3.34), and 3.23 days (95% CI: 2.99, 3.47) for DENV-1, -2, -3, and -4, respectively (Table 5 and Fig. 2 ). The median duration of viremia was 4.67 days (95% CI: 4.27, 5.12), 5.13 days (95% CI: 4.82, 5.48), 3.22 days (95% CI: 2.83, 3.72), and 3.13 days (95% CI: 2.86, 3.46) for DENV-1, -2, -3, and -4, respectively. As no significant differences were observed in duration of viremia between species (see above), estimates of duration were pooled across all species. The median time to detectable viremia of DENV was 3.23 days (95% CI: 3.00, 3.45), 2.44 days (95% CI: 2.22, 2.65), 2.89 days (95% CI: 2.67, 3.11), and 3.17 days (95% CI: 2.98, 3.37) for DENV-1, -2, -3, and -4, respectively (see Supplementary  Material) . The median duration of viremia was 4.33 days (95% CI: 4.03, 4.67), 4.84 days (95% CI: 4.52, 5.15), 3.34 days (95% CI: 3.01, 3.68), and 3.24 days (95% CI: 3.01, 3.51) for DENV-1, -2, -3, and -4, respectively (Figs. 3 and 4) .
Discussion
The results of our meta-analysis indicate that the median time to detectable viremia and duration of viremia of DENV was not statistically significantly different between non-human primate species. In rhesus macaques (Macaca mulatta), median times to detectable viremia ranged from 2.63 (95% CI: 2.40, 2.89) days for (2010) a These studies are unpublished experiments by an author (APD) conducted in 2006, 2007, and 2008. b These data were provided by Dr. S. Whitehead. The source studies are reviewed in Blaney et al. (2006) .
DENV-2 to 3.32 (95% CI: 3.01, 3.65) days for DENV-1 and median duration of viremia from 3.13 (95% CI: 2.86, 3.46) days for DENV-4 to 5.13 (95% CI: 4.82, 5.48) days for DENV-2. These estimates are shorter than those previously reported in humans. Tricou et al. (2011) reported a median duration of viremia of 6.2 days .2) for all serotypes and 6.8 days 3) for DENV-1. Vaughn et al. (2000) reported a mean duration of viremia in humans of 5.5 days for primary DENV-1 infection and 4.6 days for primary DENV-3 infection. Murgue et al. (2000) found a mean duration of 4.4 days for primary DENV infection in a cohort of French Polynesian children. However, all three of these studies estimate the duration of viremia in individuals hospitalized with dengue, and thus likely not on the first day of viremia. This would tend to underestimate the true duration of viremia. Additionally, due to selection of dengue cases based on severity (i.e., hospitalized patients) the cases included in these studies may not be representative of all dengue infections. The non-human primate studies identified here skirt these two problems directly. We found no statistically significant differences in time to-or duration of viremia between the 11 species of non-human primates studied here save for patas monkeys. Patas monkeys were found to have significantly longer times to detectable viremia and shorter duration of viremia, however, only 3 patas were infected in one study . More measurements in patas monkeys would be an important contribution as it is one of the few species from which sylvatic DENV has been isolated (Diallo et al., 2003) . Similarly, spider monkeys had a marginally significantly shorter time to detectable viremia (p ¼ 0.04) than rhesus monkeys. Interestingly, the monkeys examined here included several species of old and new world non-human primates, otherwise expected to exhibit differing physiologic and immune responses (Nunn et al., 2000) .
Interestingly, the duration of DENV-4 viremia was significantly shorter than DENV-1 and -2 after adjusting for study, species, assay and dose of inoculum. There has been clear demonstration of differences in transmission patterns (Nisalak et al., 2003) and in clinical manifestations (Balmaseda et al., 2006; Halsey et al., 2012) across the four serotypes of DENV. Shorter duration of DENV-4 viremia may account for the reduced severity observed in this serotype. Fried et al. (2010) found cases of dengue hemorrhagic fever (DHF) to be twice as likely in secondary DENV-2 and -3 infections than in secondary DENV-4. Conversely, we found DENV-2 to be statistically significantly longer than DENV-1, and -3, and -4. Balmaseda et al. (2006) found nearly double the odds of shock and internal hemorrhage with DENV-2 infection in outbreaks of DENV in Nicaragua. Nisalak et al. (2003) found DENV-3 to be associated with severe outbreaks of dengue in hospitalized cases in Bangkok, Thailand. Fox et al. (2011) found time to undetectable DENV-2 NS1 protein to be significantly longer than DENV-1. Extended durations of viremia for DENV-2 and -3 may be the cause of the increased severity of these infections and may be Table 3 Associations with time to detectable viremia. the reason for sylvatic DENV-2 which is the only serotype to have emerged in Africa from southeast Asia. We found significantly longer durations of viremia when assayed using RT-PCR or immunofluorescence as compared to plaque-forming assays. This is most likely due to a higher sensitivity of RT-PCR as compared to other, older methods for determining viremia such as plaque counting and inoculation of suckling mice. Though some of this may be due to detection of viral RNA, and not actively replicating virus. More modern methods such as ELISA and focus-forming assays were not found to be significantly different from plaque-forming assays, but this could be due to small sample sizes. The effect estimates for ELISA and FFA were 1.34 and 0.27 days longer, respectively, adjusting for study heterogeneity, serotype, species, and inoculating dose. Importantly, these differences in detection of viremia were robust to adjustment for study heterogeneity, which was considerable. Intraclass correlation coefficients indicated nearly half of the observed variance was due to differences between studies. This underlines the importance of using random effect models to account for differences between studies, and using care when interpreting results of viremia assays.
Surprisingly, increasing dose of innoculum was associated with both shorter times to detectable viremia and shorter durations of viremia. This phenomenon was observed by Martín et al. (2009a) in green monkeys, in yellow fever virus (YFV) infections in rhesus monkeys (Fox and Penna, 1943) , chimeric YF-DENV vaccine in cynomolgus macaques (Guirakhoo et al., 2004) and in humans receiving a live, attenuated Japanese Encephalitis vaccine (ChimeriVax-JE) (Monath et al., 2003 (Monath et al., , 2002 ) and a live, attenuated West Nile virus vaccine (Monath et al., 2006) . It could be that a large inoculating dose causes a rapid initial rise in viremia inducing a stronger innate immune response leading to quicker clearance. Studies in humans have found that higher peak viremia titers were positively associated with more severe disease (Tricou et al., 2011; Vaughn et al., 2000; Wang et al., 2003) ; however the evidence for an association between the magnitude and duration of viremia remains inconclusive. Vaughn et al. (2000) found the time from peak viremia to clearance was more rapid in DHF cases than in DF cases, while Fox et al. (2011) found no difference in rate of clearance between DHF and DF.
Not all studies included in this meta-analysis reported daily levels of viremia. Additional studies examining directly the relationship among inoculating dose, peak viremia and duration of Table 4 Associations with duration of viremia. Table reports the results of the univariate and multivariate mixed effects regression calculating associations between serotype, species, viremia assay used, and log 10 inoculating dose and duration of viremia. Mixed effect models included random effect for study. Univariate estimates are differences in days of viremia from the reference category of each model (denoted "Ref."), and multivariate estimates are differences in days of viremia for each covariate from rhesus monkeys infected with DENV-4 assayed using plaque count. P-values calculated using likelihood ratio tests. Durations of DENV-1 and -2 viremia are significantly longer than DENV-4 after adjusting for study, species, assay and log 10 dose. Estimates of the fixed intercept (β 0 ) and variance of the random intercept are presented (s). viremia are necessary, as well as studies investigating the effects of preexisting immunity on time to viremia and duration. Our methods separately accounted for the two largest potential sources of bias: random effect models accounted for study heterogeneity and doubly-interval censored survival analysis accounted for the large amount of censoring (right-, left-and both) present in reported days of non-human primate viremia. While the random effect model did not take into account the effects of censoring, the amount of censoring only differed in DENV-2 and common marmoset samples, and inferences drawn from them are useful for examining associations between covariates of interest and the time to detectable viremia and duration of viremia. Even though the random effect model accounts for most of the heterogeneity between studies, some caution must still be used when interpreting the results of the associations as some residual confounding may exist from remaining heterogeneity between studies. Finally, while all efforts were made to find all studies reporting non-human primate viremia, it is possible that some studies were missed, or that some data were not published (Dickersin et al., 1990) .
Our study provides estimates of the times to detectable viremia and durations of DENV-1-4 viremia in multiple non-human primate species, both Old World and New World, and identifies how these differ across serotype, viremia assay, non-human primate species and inoculating dose. Few if any studies have directly compared DENV infection in multiple non-human primates. Our results further understanding of within host DENV replication kinetics which are especially important in how they influence transmission dynamics. In the light of new dengue vaccine trials (Halstead, 2012; Sabchareon et al., 2012) , sylvatic DENV infection in non-human primates could provide a source of infectious introductions. An accurate and thorough understanding of the sylvatic cycle of dengue, including the roles of the various non-human primate species in transmission, may allow prediction of epidemics within non-human primates and thereby lessen the impact of spillover on humans living in areas of overlap with nonhuman primate hosts. Our results also are important in parameterizing dynamic models of dengue (Althouse et al., 2012) , and further understanding of DENV transmission dynamics in general, including differences in serotype-specific cycles.
Methods
Systematic review
We searched PubMed, Web of Science and Google scholar for articles containing the terms "dengue primate viremia infection", "dengue viremia primates", "dengue viremia monkey", "dengue vaccine primates", and "dengue infection primates". We narrowed our focus to primary infections where details on the infecting virus were reported. Our inclusion criteria were:
1. The non-human primate must be DENV naïve at the time of experimental infection (including free of exposure to experimental vaccines). 2. The challenge serotype (DENV-1-4) and the specific virus strain (with passage number, if applicable) must be clearly identified and the dosage of virus stated (in plaque forming units [PFU] ), and 3. The presence of viremia must be reported on a day-by-day basis, at least two time points, either in a graph or table, and not in a summary statistic. This does not preclude monkeys bled sporadically (e.g., every other day).
Additional (unpublished) studies were identified through expert consultation. Abstracts were doubly reviewed (BMA, DATC).
Time to event data
A survival analytic approach was used to determine time-toevent (viremia or clearance). If more than one method for assessing viremia was used, the method with the higher sensitivity was reported (though multiple methods were compared). Data were classified as fully observed, single-or doubly-interval censored. Observations were fully observed if the non-human primates were bled and found not to be viremic before and after being found viremic. If non-human primates were found to be viremic on the first or last sample taken, then the data point was assumed single-interval censored. If non-human primates were viremic on both the first and last sample, then the data point was assumed doubly-interval censored imposing left and right boundaries of inoculation and 16 days (estimates are insensitive to this number, see Supplementary Material). Observations missing or negative surrounded by two viremic samples were assumed to be viremic. Methods for analyzing doubly-interval censored data have been developed previously (Reich et al., 2009) . We estimate the time to detectable viremia and the duration of viremia, both of which we assume are log-normally distributed (see Supplementary Material). We stratify by DENV serotype and compute bootstrap confidence intervals.
Associations with time to viremia and duration
To explore the potential association between length of time to detectable viremia and duration of viremia, linear and random effect models were fit with time to viremia or duration as the outcome, a random effect for study and serotype, inoculating dose, viremia assay, and species of non-human primate as potential covariates of interest (Fitzmaurice et al., 2011) . As these models do not directly take into account the effects of censoring, we test for differences censoring between covariates. Linear and mixed effect models are compared using the Akaike information criterion (AIC) (Burnham et al., 2002) .
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Benjamin M. Althouse, Anna P. Durbin, Kathryn A. Hanley, Scott B. Halstead, Scott C. Weaver, Derek A. T. Cummings Figure S1 reports the genotypes represented in the identified studies. Genotype names are as reported as in the study. Tables S1 and S2 show univariate and multivariate linear regression results associating time to-and duration of viremia with serotype, species, assay, and inoculating dose. Ignoring the heterogeneity between studies results in many covariates being significantly associated with DENV viral kinetics. Table S2 : Linear Associations with the Duration of Viremia Table reports the results of the univariate and multivariate linear regression calculating associations between serotype, species, viremia assay used, and log 10 inoculating dose and duration of viremia. Estimates are di↵erences in days of viremia for each covariate from rhesus monkeys infected with DENV-2 assayed using plaque count. Table S3 reports Akaike information criterion (AIC) values for the linear and random e↵ects models and likelihood ratio tests for di↵erences between models. We find random e↵ects models are universally favored over linear models. Table S3 : Model Selection Table reports the reports AIC values for the linear ("Lin.") and random e↵ects ("R.E.") models and likelihood ratio tests for di↵erences between models. Table S4 reports the results of the multivariate random e↵ects regression for duration of viremia with DENV-2 as the reference serotype. We find durations of DENV-1, -3, and -4 viremia are significantly shorter than DENV-2 after adjusting for study, species, assay and log 10 dose. Table S4 : Associations with Duration of Viremia, DENV-2 as Reference Table reports the results of the multivariate mixed e↵ects regression calculating associations between serotype, species, viremia assay used, and log 10 inoculating dose and duration of viremia with DENV-2 as the reference category. Mixed e↵ects models included random e↵ect for study. Estimates are di↵erences in days of viremia for each covariate from rhesus monkeys infected with DENV-2 assayed using plaque count. Pvalues calculated using likelihood ratio tests. Durations of DENV-1, -3, and -4 viremia are significantly shorter than DENV-2 after adjusting for study, species, assay and log 10 dose. Estimates of the fixed intercept ( 0 ) and variance of the random intercept are presented ( ). Figures S2 and S3 show histograms of the time to-and duration of DENV-1-4 viremia, respectively, pooled across non-human primates with maximum likelihood log-normal fits. 
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